Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

Patients regularly taking Eli Lilly & Co.’s obesity shot Zepbound tend to keep the weight off for at least three years, with ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a cardioprotective benefit won’t be answered until Phase 3 tests read out.

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart health.

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...